

# ORCHARD Trial

Osimertinib plus datopotamab deruxtecan in patients with *EGFR*-mutated advanced NSCLC post-progression on first-line osimertinib

Riess JW, Yu HA, Le X, et al. *Ann Oncol*. 2026.S0923-7534(26)00070-0




ANNENBERG CENTER FOR HEALTH SCIENCES

AT EISENHOWER

Imparting knowledge. Improving patient care.

# ORCHARD: Efficacy



# ORCHARD: Safety

| Adverse Events                                     | Osimertinib + DatoDXd 4mg/kg | Osimertinib + DatoDXd 6mg/kg |
|--|------------------------------|------------------------------|
| <b>Grade <math>\geq 3</math></b>                   | <b>49%</b>                   | <b>76%</b>                   |
| <b>Most Common</b>                                 |                              |                              |
| Stomatitis   | <b>66%</b>                   | <b>76%</b>                   |
| Nausea   | <b>57%</b>                   | <b>74%</b>                   |
| Alopecia   | <b>51%</b>                   | <b>68%</b>                   |
| <b>Serious</b>                                     | <b>31%</b>                   | <b>44%</b>                   |
| <b>Interstitial Lung Disease (ILD)/pneumonitis</b> | <b>3%</b>                    | <b>15%</b>                   |
| <b>Leading to Dato-DXd dose reduction</b>          | <b>23%</b>                   | <b>59%</b>                   |

